Albanien
Bosnien-Herzegowina
Bulgarien
Kroatien
Zypern
Tschechische Republik
Dänemark
Estland
Deutschland
Ungarn
Italien
Kosovo
Lettland
Litauen
Luxemburg
Mazedonien
Montenegro
Polen
Portugal
Rumänien
Serbien
Slowakei
Slowenien
Spanien
Schweiz
Schweden
Truthahn
Vereinigtes Königreich
Vereinigte Arabische Emirate
Hongkong
Kuwait
Libanon
Südafrika
Deutsch 
English 
Български 
Français 
Ελληνικά 
Magyar 
Italiano 
Cрпски 
Español
Zusammenfassung
behandelte Patienten
Hat schon einmal jemand von Stammzellen profitiert?
Nabelschnurblutzellen wurden 1988 in Frankreich erstmals erfolgreich eingesetzt. Einige Jahre später, 2007, führte die FamiCord Group diese Methode auch in Polen ein. Bislang wurden weltweit über 40.000 Nabelschnurblutstammzellen transplantiert und so Menschenleben und Gesundheit gerettet.
Die FamiCord Group ermöglicht ihren Kunden innovative Behandlungen mit Stammzellen. Sehen Sie sich die vollständige Liste der Patienten an, die mit unterschiedlichen Erkrankungen davon profitiert haben.
Patientenliste
| NEIN. | Quelle | Quellentyp | Diagnose | Medizinischer Sektor | Jahr der Bewerbung | Therapie | Land | Alter des Empfängers |
|---|---|---|---|---|---|---|---|---|
| 3801 | Apheresis | allogen | No Data | Hämatologie | 2019 | Standardtherapie | Polen | 58 |
| 3802 | Apheresis | allogen | Non-Hodgkin-Lymphom | Hämatologie | 2019 | Standardtherapie | Polen | 68 |
| 3803 | Apheresis | allogen | Non-Hodgkin-Lymphom | Hämatologie | 2019 | Standardtherapie | Polen | 28 |
| 3804 | Apheresis | allogen | Non-Hodgkin-Lymphom | Hämatologie | 2019 | Standardtherapie | Polen | 58 |
| 3805 | Apheresis | allogen | Non-Hodgkin-Lymphom | Hämatologie | 2019 | Standardtherapie | Polen | 67 |
| 3806 | Apheresis | allogen | Non-Hodgkin-Lymphom | Hämatologie | 2019 | Standardtherapie | Polen | 51 |
| 3807 | Apheresis | allogen | Non-Hodgkin-Lymphom | Hämatologie | 2019 | Standardtherapie | Polen | 65 |
| 3808 | Apheresis | allogen | Non-Hodgkin-Lymphom | Hämatologie | 2019 | Standardtherapie | Polen | 42 |
| 3809 | Apheresis | allogen | Non-Hodgkin-Lymphom | Hämatologie | 2019 | Standardtherapie | Polen | 55 |
| 3810 | Apheresis | Autolog | Non-Hodgkin-Lymphom | Hämatologie | 2019 | Standardtherapie | Deutschland | 56 |
| 3811 | Apheresis | Autolog | Non-Hodgkin-Lymphom | Hämatologie | 2019 | Standardtherapie | Deutschland | 59 |
| 3812 | Apheresis | Autolog | Non-Hodgkin-Lymphoma-Relapse | Hämatologie | 2019 | Standardtherapie | Deutschland | 63 |
| 3813 | Apheresis | Autolog | Non-Hodgkin-Lymphoma-Relapse | Hämatologie | 2019 | Standardtherapie | Deutschland | 69 |
| 3814 | Apheresis | allogen | Osteomyelofibrosis – Other | Hämatologie | 2019 | Standardtherapie | Polen | 63 |
| 3815 | Apheresis | allogen | Other Myelofibrosis | Hämatologie | 2019 | Standardtherapie | Polen | 70 |
| 3816 | Apheresis | allogen | Other Myelofibrosis | Hämatologie | 2019 | Standardtherapie | Polen | 61 |
| 3817 | Apheresis | allogen | Other Myelofibrosis | Hämatologie | 2019 | Standardtherapie | Polen | 50 |
| 3818 | Apheresis | allogen | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Hämatologie | 2019 | Standardtherapie | Polen | 24 |
| 3819 | Apheresis | allogen | Plasma Cell Leukemia | Hämatologie | 2019 | Standardtherapie | Polen | 35 |
| 3820 | Apheresis | allogen | Polycythemia Vera-Myelofibrosis | Hämatologie | 2019 | Standardtherapie | Deutschland | 58 |
| 3821 | Apheresis | allogen | Post–Polycythemia Vera Myelofibrosis | Hämatologie | 2019 | Standardtherapie | Deutschland | 70 |
| 3822 | Apheresis | Autolog | Primary Central Nervous System Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 65 |
| 3823 | Apheresis | Autolog | Primary Central Nervous System Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 63 |
| 3824 | Apheresis | Autolog | Primary Central Nervous System Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 69 |
| 3825 | Apheresis | Autolog | Primary Central Nervous System Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 64 |
| 3826 | Apheresis | Autolog | Primary Central Nervous System Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 56 |
| 3827 | Apheresis | Autolog | Primary Central Nervous System Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 57 |
| 3828 | Apheresis | Autolog | Primary Central Nervous System Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 63 |
| 3829 | Apheresis | Autolog | Primary Central Nervous System Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 67 |
| 3830 | Apheresis | Autolog | Primary Central Nervous System Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 78 |
| 3831 | Apheresis | allogen | Primärer Immundefekt | Hämatologie | 2019 | Standardtherapie | Polen | 21 |
| 3832 | Apheresis | allogen | Primärer Immundefekt | Hämatologie | 2019 | Standardtherapie | Polen | 19 |
| 3833 | Apheresis | allogen | Primary Mediastinal | Hämatologie | 2019 | Standardtherapie | Polen | 33 |
| 3834 | Apheresis | allogen | Primäre Myelofibrose | Hämatologie | 2019 | Standardtherapie | Polen | 46 |
| 3835 | Apheresis | allogen | Primäre Myelofibrose | Hämatologie | 2019 | Standardtherapie | Polen | 45 |
| 3836 | Apheresis | allogen | Primäre Myelofibrose | Hämatologie | 2019 | Standardtherapie | Deutschland | 55 |
| 3837 | Apheresis | allogen | Relapsed Peripheral T Cell Lymphoma | Hämatologie | 2019 | Standardtherapie | Polen | 65 |
| 3838 | Apheresis | allogen | Secondary Acute Myeloid Leukemia | Hämatologie | 2019 | Standardtherapie | Polen | 59 |
| 3839 | Apheresis | allogen | Secondary Acute Myeloid Leukemia | Hämatologie | 2019 | Standardtherapie | Deutschland | 64 |
| 3840 | Apheresis | allogen | Secondary Acute Myeloid Leukemia | Hämatologie | 2019 | Standardtherapie | Deutschland | 60 |
| 3841 | Apheresis | allogen | Secondary Acute Myeloid Leukemia At Myeloproliferative Neoplasms | Hämatologie | 2019 | Standardtherapie | Deutschland | 56 |
| 3842 | Apheresis | Autolog | Secondary Primary Central Nervous System Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 66 |
| 3843 | Apheresis | allogen | Schwere aplastische Anämie | Hämatologie | 2019 | Standardtherapie | Polen | 12 |
| 3844 | Apheresis | allogen | Schwere aplastische Anämie | Hämatologie | 2019 | Standardtherapie | Polen | 11 |
| 3845 | Apheresis | allogen | Schwere aplastische Anämie | Hämatologie | 2019 | Standardtherapie | Polen | 55 |
| 3846 | Apheresis | allogen | Schwerer kombinierter Immundefekt | Hämatologie | 2019 | Standardtherapie | Polen | 1 |
| 3847 | Apheresis | allogen | T-Cell Acute Lymphoblastic Leukemia | Hämatologie | 2019 | Standardtherapie | Polen | 44 |
| 3848 | Apheresis | Autolog | T-Cell Non-Hodgkin Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 55 |
| 3849 | Apheresis | Autolog | T-Cell Non-Hodgkin Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 59 |
| 3850 | Apheresis | allogen | T-Cell Non-Hodgkin Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 67 |
| 3851 | Apheresis | allogen | T-Cell Non-Hodgkin Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 45 |
| 3852 | Apheresis | Autolog | T-Cell Non-Hodgkin Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 72 |
| 3853 | Apheresis | Autolog | T-Cell Non-Hodgkin Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 61 |
| 3854 | Apheresis | Autolog | T-Cell Non-Hodgkin Lymphoma | Hämatologie | 2019 | Standardtherapie | Deutschland | 61 |
| 3855 | Apheresis | Autolog | Testicular Cancer Relapse | Hämatologie | 2019 | Standardtherapie | Deutschland | 29 |
| 3856 | Apheresis | allogen | Thalassemia Major | Hämatologie | 2019 | Standardtherapie | Polen | 20 |
| 3857 | Apheresis | allogen | Wiskott-Aldrich Syndrome | Hämatologie | 2019 | Standardtherapie | Polen | 1 |
| 3858 | Apheresis | allogen | Β – Thalassemia | Hämatologie | 2019 | Standardtherapie | Polen | 13 |
| 3859 | Adipose Tissue | Autolog | Chondromalacia | Orthopädie | 2019 | Experimentelle Therapie | Polen | 48,8 |
| 3860 | Adipose Tissue | Autolog | Chondromalacia | Orthopädie | 2019 | Experimentelle Therapie | Polen | 38,6 |
| 3861 | Adipose Tissue | Autolog | Coxarthrosis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 34 |
| 3862 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3863 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3864 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3865 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3866 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3867 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3868 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3869 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3870 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3871 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3872 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3873 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3874 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3875 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3876 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3877 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3878 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3879 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3880 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3881 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3882 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3883 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3884 | Adipose Tissue | Autolog | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3885 | Adipose Tissue | Autolog | Gonarthrosis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 44,11 |
| 3886 | Adipose Tissue | Autolog | Gonarthrosis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 65,3 |
| 3887 | Adipose Tissue | Autolog | Gonarthrosis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 68,6 |
| 3888 | Adipose Tissue | Autolog | Gonarthrosis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 36,1 |
| 3889 | Adipose Tissue | Autolog | Gonarthrosis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 54,3 |
| 3890 | Adipose Tissue | Autolog | Mild Arthritis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 21,2 |
| 3891 | Adipose Tissue | Autolog | Mild Arthritis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 68,5 |
| 3892 | Adipose Tissue | Autolog | Osteoarthritis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 52,8 |
| 3893 | Adipose Tissue | Autolog | Osteoarthritis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 44,8 |
| 3894 | Adipose Tissue | Autolog | Osteoarthritis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 52,5 |
| 3895 | Adipose Tissue | Autolog | Osteoarthritis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 54,5 |
| 3896 | Adipose Tissue | Autolog | Osteoarthritis | Orthopädie | 2019 | Experimentelle Therapie | Polen | 55,11 |
| 3897 | Adipose Tissue | Autolog | Scar | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3898 | Adipose Tissue | Autolog | Scar | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3899 | Adipose Tissue | Autolog | Scar | Dermatology | 2019 | Clinical Trial | Polen | no data |
| 3900 | Adipose Tissue | Autolog | Scar | Dermatology | 2019 | Clinical Trial | Polen | no data |